STOCKHOLM, SE / ACCESS Newswire / May 22, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, May 22, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

A recent study published in Cardiovascular Diabetology reveals that Sacubitril/Valsartan, a combination of a neprilysin ...

Discover effective strategies to lower resistant high blood pressure, from medication evaluation and dietary changes to ...

Background— Activation of the renin-angiotensin system (RAS ... The levels of PRA, Ang II, and myocardium ACE activity were measured by the Wake Forest University Health Sciences Hypertension Core ...

Travere Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) ...

Alzheimer's disease is the most common type of dementia, but following closely behind (affecting an estimated 5 to 10 percent ...

Increased TGF-β1 promotes the phosphorylation and nuclear translocation of Smad2/3, sequentially activating the transcription ...

Role of the RAAS in the Pathophysiology of Heart Failure ACE inhibitors have no effect on angiotensin II formed by alternate pathways. In contrast, ARBs would be expected to inhibit the biologic ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Rationale: The vasoactive peptide angiotensin II (Ang II) is a potent cardiotoxic hormone whose actions have been well studied, yet questions remain pertaining to the downstream factors that mediate ...